Effectiveness of Tai Chi vs Cognitive Behavioural Therapy for Insomnia in Middle-Aged and Older Adults
November 27, 2025
Brand Name :
Triferic, Tiferic AVNU
Synonyms :
Ferric pyrophosphate citrate
Class :
Iron products
Dosage Forms & StrengthsÂ
Injectable solutionsÂ
27.2mg/5mlÂ
Powder for injectionÂ
272mgÂ
For the final hemodialysate to contain a two micromolar (110 mcg/L) quantity of iron (III), add to the bicarbonate concentrate
Note:
Ferric pyrophosphate citrate is not advised in peritoneal dialysis
The efficacy of the drug in home dialysis is not been studied
Indication:
The drug is indicated for use as an iron replacement to maintain hemoglobin levels in HDD-CKD (hemodialysis-dependent chronic kidney disease)
Safety and efficacy studies have not been establishedÂ
Refer to adult dosingÂ
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with aluminum hydroxide
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferric ammonium citrate
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferric cation
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferric maltol
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferric sulfate
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferrous fumarate
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferrous succinate
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferrous sulfate anhydrous
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferumoxides
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferumoxytol
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with iron
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with iron dextran
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with magnesium carbonate
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with magnesium hydroxide
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with magnesium silicate
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with nitroprusside
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with Prussian blue
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with sodium feredetate
Actions and spectrum:Â
The strong complex formation between these two species serves as the basis for the use of ferric pyrophosphate. In addition, pyrophosphate could cause transferrin to release iron, enhance transferrin to ferritin transfer, and stimulate transferrin molecules to exchange iron. Due to this, it is the best choice for parenteral administration, delivery of iron into the bloodstream, and hemoglobin incorporation.Â
Frequency not definedÂ
ItchingÂ
Chest tightnessÂ
Swelling of mouth, tongue, throat, lips or faceÂ
WheezingÂ
Trouble breathingÂ
Burning urinationÂ
Pain in the lower abdomenÂ
Pain in the pelvisÂ
Black Box Warning Â
This drug can cause harm the fetus if administered when pregnantÂ
Contraindication/Caution:Â
Contraindication:Â
NoneÂ
Pregnancy consideration:Â Â
USFDA pregnancy category: Not assignedÂ
Lactation:Â Â
The excretion of the drug into human milk is not known.Â
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Pharmacodynamics:Â
The synthesis of hemoglobin in bone marrow uses the available iron. Increased transferrin-bound iron, serum iron, and iron stored in hepatocytes and macrophages as ferritin are commonly observed after iron supplementation.Â
Pharmacokinetics:Â
AbsorptionÂ
83-94% of bioavailability can be observedÂ
The area under the curve: 675-1840mcg.h/dlÂ
Cmax: 113-261mcg/dlÂ
DistributionÂ
The volume of distribution after administration through the intravenous route is 0.765 to 0.859LÂ
MetabolismÂ
Ferric pyrophosphate metabolism is similar to the body’s biological processing of iron, which is absorbed in the stomach and then released into the bloodstream.Â
Elimination and excretionÂ
Ferric pyrophosphate citrate undergoes elimination through urine, hair, feces, sweat, and nails. Â
Half-life:Â
1.48 hoursÂ
Administration:Â
Ferric pyrophosphate citrate is administered intravenously under the supervision of a medical practitioner
Patient information leafletÂ
Generic Name: ferric pyrophosphate citrate Â
Why do we use ferric pyrophosphate citrate?Â
For the treatment of iron deficiency or loss, ferric pyrophosphate citrate is recommended in order to help maintain hemoglobin levels and lower the required dosage of ESA (erythropoiesis-stimulating agent).Â